					SHEET TOF &
FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET N ACADIA.011DV	= -	APPLICATION N Filed herewith 10/	o. 623,119
**** **********************************	DISCLOSURE STATEMENT Y APPLICANT	APPLICANT Andersson, et al.			
(USE SEVERAL	SHEETS IF NECESSARY)	FILING DATE Filed herewith	07/17/03	GROUP Unknown	1625

	U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE	
CC	1	4,458,075	07/1984	Davis, et al.	546	198		
	2	4,870,085	09/1989	Glaser, et al.	514	323		
	3	5,654,320	08/1997	Catlow, et al.	514	322		
CC	4	5,703,070	12/1997	Lavielle et al.	514	212		
	Ш	· · · · · · · · · · · · · · · · · · ·						
	Ш							
	Ш							
	\sqcup							
]	}				

	FOREIGN PATENT DOCUMENTS								
EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION	
INITIAL			-				YES	NO	
CC	5	DE 4039631 A1	06/1992	DE					
	6	6511642	03/1966	NL					
	7	WO 98/20548	07/1998	PCT					
CC	8	WO 98/57953	12/1998	PCT					
			<u> </u>						

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
cc	9 Asahi Chem., 3-aminoindazole derivatives, CA 101:23469 (1983)
	Dutta, et al., Highly selective, novel analogs of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine for the dopamine transporter: effect of different aromatic substitutions on their affinity and selectivity, CA 126:69745 (1997)
	11 Fujimura, et al., Indazole derivatives, CA 87:53273 (1976)
	12 Hanning, et al., Preparation of some derivatives of 5-methyl-indazole-3-carboxylic acid, CA 80:82791 (1973)
CC	Lounasmaa, M., et al., Acid-catalyzed epimerization of indolo[2,3-α]quinolizidines. 1-,2- and 3-monosubstituted alkyl derivatives, Tetrahedron, 53(14):5349-5356 (1997)

EXAMINER /Celia Chang/	DATE CONSIDERED 06/01/2006
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION	S IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT

I EXAMINER: WITH LIFE CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

CHEET 2 OF

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. ACADIA.011DV1	APPLICATION NO. Filed herewith
INFORMATION DISCLOSURE STATEMENT		10/623,119
BY APPLICANT	APPLICANT Andersson, et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE 07/17 Filed herewith	7/03 GROUP 1625 Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
cc	l	Lounasmaa, M., et al., Stereochemical course of the modified polonovski reaction and meucuric acetate oxidation in the preparation of 2-substituted 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-α]quinolizines, Tetrahedron, 47(32):6371-6380 (1991)				
	15	Lounasmaa, M., et al., Stereoregulation of the c(12b)H-C(2)H relationship in the preparation of 2-substituted 1,2,3,4,6,7,12,12b-octahydroindolo[2,3-α]quinolizines, Tetrahedron, 44(12):3975-3992 (1989)				
\	16	Minieri, et al., Bactericidal and fungicidal 1-(aminomethyl)indazoles, CA 79:442494 (1973)				
	17	Orth, et al., Centrally acting isosteric Mannich bases, CA 70:11473 (1968)				
	18	Pavia, et al., "Structure activity" CA 118:6834 (1992)				
	19	Rao, et al., Synthesis and radioprotective activity of .beta(3-indazolyl)ethylamine derivatives, CA 108:94460 (1987)				
	20	Synthelabo, Preparation of 1-[(hetero)aroyl]-4-(4-imidazolyl)piperidines as serotoninergic receptor antagonists, CA 121:9402 (1994)				
	21	Zenitz, et al., *1-indolylglyoxalyl)piperidines, CA 64:67726 (1965)				
CC	22	Sample compounds				

S:\DOC\$\\$KT\\$KT-3996.DOC 071703

EXAMINER	/Celia Chang/	DATE CONSIDERED	06/01/2006
			
FYAMINER- INITIAL IF	CITATION CONSIDERED WHETHER OR NOT CITATIO	N IS IN CONFORMANCE WITH ME	SED 800: DDAW LINE TUDOLICU CITATION IE NOT

PTO/SB/08 Equivalent

FORMATION DISCLOSURE STATEMENT BY APPLICANT

	Application No.	10/623,119
	Filing Date	July 17, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1614- 1625
-	Examiner	Unknown Chang
	Attorney Docket No.	ACADIA.011DV1

(Multiple sheets used when necessary) SHEET 1 OF 1

	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear				
CC	1	US 5,494,908	02-27-1996	O'Malley et al.					
	2	US 5,580,982	12-03-1996	O'Malley et al					
	3	US 5,756,754	05-26-1998	O'Malley et al					
	4	US 5,925,766	07-20-1999	O'Malley et al					
cc	5	US 6,046,203	04-04-2000	O'Malley et al					

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹	
CC	6	WO 94/12495	02-15-2003	Hoest-Russel Pharm. Inc.			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
CC	7	Davis, et al. 3-Substituted-1-2-Benzisoxazoles: Novel Antipsychotic Agents, Drug Design and Discovery, Vol 8, No. 3 1992, Harwood Academic Publishers GmbH, pp225-240; XP000608016.	

1761286 060905

Examiner Signature /Celia Chang/ **Date Considered**

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/01/2006

T¹ - Place a check mark in this area when an English language Translation is attached.